Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 40

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 30, 2024Patents$21,728 $14,873 $— $6,855 14License3,129 1,422 — 1,707 21Total intangible assets, net$24,857 $16,295 $— $8,562 Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March 31, 2025 and 2024.Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for the three months ended March 31, 2025 and 2024, and $0.9 million for each of six months ended March 31, 2025 and 2024. None of the intangible assets with definite useful lives are anticipated to have a residual value.The following table presents the estimated future amortization expense related to intangible assets as of March 31, 2025:Amortization ExpenseYear Ending September 30, (in thousands)2025 (remainder)$849 20261,700 20271,700 20281,700 2029795 2030 and thereafter967 Total$7,711 

13

NOTE 6. STOCKHOLDERS’ EQUITY

The following table summarizes the Company’s shares of common stock and preferred stock:SharesPar ValueAuthorizedIssuedOutstanding(in thousands)As of March 31, 2025Common stock$0.001 290,000 138,062 138,062 Preferred stock$0.001 5,000 — — As of September 30, 2024Common stock$0.001 290,000 124,376 124,376 Preferred stock$0.001 5,000 — —  As of March 31, 2025 and September 30, 2024, respectively, 10,134,173 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company’s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  On November 25, 2024,